Hexima: Edison Open House Healthcare 2022

Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis).

• Tell us about Hexima’s work on antifungal agents.
• What are some of the issues with the currently available antifungals?
• Please explain onychomycosis and why the current treatments for it are inadequate?
• What is the situation with regards to intellectual property?
• What is the impact for those who might be immunocompromised?
• With regards to commercialisation plans, are you seeking partnerships or licensing agreements?
• Are there other indications for pezadeftide?
• How many years do you think you have before pezadeftide also becomes resistant?
• Which milestones should investors focus on in the coming year?

Stream all the content: https://www.edisongroup.com/edison-open-house-global-healthcare-2022/